Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant norovirus vaccine
- Development stage
- Unknown
- Lead developer
- Grand-Sevax Life Sciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The quadrivalent recombinant norovirus vaccine is a virus-like particle (VLP) vaccine developed by Grand Sevax Life Sciences (a subsidiary of Grand Pharma). It is produced using a *Hansenula polymorpha* (Hansen yeast) expression system and targets four major norovirus genotypes: GII.2, GII.4, GII.6, and GII.17. The vaccine is composed of recombinant VP1 capsid proteins from these genotypes, which self-assemble into non-infectious VLPs that mimic the structure of the native virus to elicit a protective immune response. It is currently being evaluated in Phase 1 clinical trials in China for the prevention of acute gastroenteritis caused by norovirus infection in individuals aged 6 months and older.
- Other names
- Quadrivalent recombinant norovirus vaccine (Hansen yeast)四价重组诺如病毒疫苗（汉逊酵母）
02
Targets
BCR (Immunoglobulin G B Cell Receptor)GII.17 VP1 (Norovirus GII.17 VP1)VP1 (Norovirus GII.2 major capsid protein VP1)GII.4 VP1 (Norovirus GII.4 VP1)
Beyond the preview
Go deeper on quadrivalent recombinant norovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant norovirus vaccine.